Loading...

Think a new tankless iNO system can give you more time in your workday?
Think Again!

The ULSPIRA Solution™ offers you a choice of helpful services to make every workday easier

Customizable ULSPIRA Care+™ services give you more time with patients instead of handling routine tasks

Tired of counting and moving NO tanks for treatment?

Think Again — With ULSPIRA Care+, our highly trained TGM team will count, inventory, replace and transport your NO tanks for your entire RT department.

Hassled by keeping enough iNO supplies on hand?

Think Again — Your ULSPIRA Care+ TGM team will track inventory, order supplies and stock your shelves so that you can focus on caring for your patients.

Concerned about storage space for gas cylinders?

Think Again — Opting for ULSPIRA Care+ means we store your tanks for you and our TGM team will deliver them as often as needed, keeping your storage area clutter‑free.

Worried your devices won't be ready for iNO treatment?

Think Again — Your TGM team will perform required high calibrations and Pre-Use Checks on your ULSPIRA TS™, so you’re ready to go when patients need therapy.

Now there’s a total solution for iNO therapy in the NICU

It’s Time to Think Again. It’s Time to Learn More.

alt_text

Inspire breath into life with a human‑centered solution
alt_text

Specialist expertise with complete customer support
alt_text

The iNO therapy device for more safety and supply
alt_text

Customizable services to reduce your workload

ULSPIRA Indication and Important Safety Information

ULSPIRA (nitric oxide) gas, for inhalation, is a vasodilator indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

Contraindications

ULSPIRA is contraindicated in neonates dependent on right-to-left shunting of blood.

Warnings and Precautions

  • Rebound: Abrupt discontinuation of ULSPIRA may lead to worsening oxygenation and increasing pulmonary artery pressure.
  • Methemoglogin: Methemoglobin increases with the dose of ULSPIRA and is dose dependent. Following discontinuation or reduction of nitric oxide, methemoglobin levels can take up to 8 hours or more to return to baseline. If methemoglobin levels do not resolve with decrease in dose or discontinuation of ULSPIRA, additional therapy may be warranted to treat methemoglobinemia.
  • Elevated Levels: Monitor for PaO2, inspired nitrogen dioxide (NO2), and methemoglobin during ULSPIRA administration.
  • Heart Failure: In patients with pre-existing left ventricular dysfunction, ULSPIRA may increase pulmonary capillary wedge pressure, leading to pulmonary edema.
  • Nitrogen dioxide may cause airway inflammation and damage to lung tissues.

Adverse Reactions

The most common adverse reaction of ULSPIRA is hypotension.

Drug Interactions

Nitric Oxide donor compounds may increase the risk of developing methemoglobinemia.

Use With Delivery System

ULSPIRA must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System operated by trained personnel. Only validated ventilator systems should be used in conjunction with ULSPIRA.

Adverse Events

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full ULSPIRA prescribing information for additional ULSPIRA safety and risk information.

ULSPIRA TS Safety Statement

Intended Use

The ULSPIRA TS Nitric Oxide Therapy System is intended for use by healthcare professionals for the delivery of nitric oxide (NO) and the monitoring of inspired NO, NO2 and O2 concentrations for a patient undergoing inhaled Nitric Oxide (iNO) therapy.

ULSPIRA TS must only be used in accordance with the indications, contraindications, warnings and precautions described in the nitric oxide drug packaging inserts and labeling, and is indicated for use in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension. The primary targeted clinical setting is the Neonatal Intensive Care Unit (NICU) and secondary targeted clinical setting is the transport of neonates. Refer to this material prior to use.

In the case of an abrupt stop of inhaled NO gas delivery, withdrawal (rebound pulmonary hypertension) may occur. Possible side-effects of the inhaled NO gas therapy are further described in the nitric oxide drug packaging inserts and labeling.

ULSPIRA TS can be used with respiratory devices. Make sure that ULSPIRA TS is validated with the respiratory device you use. Validated respiratory devices are listed in the User's Manual.

Device Warnings:

  • Persons using ULSPIRA TS must be trained and experienced in its use to ensure effective administration of nitric oxide and to avoid injury to the patient or to others resulting from inhalation of excess NO, NO2 or other reaction products.
  • Always perform a Pre-Use Check before connecting ULSPIRA TS to the patient. Only use the system if the Pre-Use Check is successfully passed.
  • If an unintended treatment interruption occurs, use the backup system.
  • ULSPIRA TS must not be used in an MRI environment.

Rx Only

ULSPIRA Indication and Important Safety Information

Click here to read more

ULSPIRA (nitric oxide) gas, for inhalation, is a vasodilator indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

Contraindications

ULSPIRA is contraindicated in neonates dependent on right-to-left shunting of blood.

Warnings and Precautions

  • Rebound: Abrupt discontinuation of ULSPIRA may lead to worsening oxygenation and increasing pulmonary artery pressure.
  • Methemoglogin: Methemoglobin increases with the dose of ULSPIRA and is dose dependent. Following discontinuation or reduction of nitric oxide, methemoglobin levels can take up to 8 hours or more to return to baseline. If methemoglobin levels do not resolve with decrease in dose or discontinuation of ULSPIRA, additional therapy may be warranted to treat methemoglobinemia.
  • Elevated Levels: Monitor for PaO2, inspired nitrogen dioxide (NO2), and methemoglobin during ULSPIRA administration.
  • Heart Failure: In patients with pre-existing left ventricular dysfunction, ULSPIRA may increase pulmonary capillary wedge pressure, leading to pulmonary edema.
  • Nitrogen dioxide may cause airway inflammation and damage to lung tissues.

Adverse Reactions

The most common adverse reaction of ULSPIRA is hypotension.

Drug Interactions

Nitric Oxide donor compounds may increase the risk of developing methemoglobinemia.

Use With Delivery System

ULSPIRA must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System operated by trained personnel. Only validated ventilator systems should be used in conjunction with ULSPIRA.

Adverse Events

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full ULSPIRA prescribing information for additional ULSPIRA safety and risk information.

Please complete the form to connect with an expert at Airgas.

Talk to an expert about your gases, hardgoods and safety needs.

Thank You!

We received your request.

An Airgas expert will contact you shortly.